195 related articles for article (PubMed ID: 36533670)
41. Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept.
Lin P; Medeiros LJ
Adv Anat Pathol; 2005 Sep; 12(5):246-55. PubMed ID: 16210920
[TBL] [Abstract][Full Text] [Related]
42. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract][Full Text] [Related]
43. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.
Tournilhac O; Santos DD; Xu L; Kutok J; Tai YT; Le Gouill S; Catley L; Hunter Z; Branagan AR; Boyce JA; Munshi N; Anderson KC; Treon SP
Ann Oncol; 2006 Aug; 17(8):1275-82. PubMed ID: 16788002
[TBL] [Abstract][Full Text] [Related]
44. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
Sewastianik T; Guerrera ML; Adler K; Dennis PS; Wright K; Shanmugam V; Huang Y; Tanton H; Jiang M; Kofides A; Demos MG; Dalgarno A; Patel NA; Nag A; Pinkus GS; Yang G; Hunter ZR; Jarolim P; Munshi NC; Treon SP; Carrasco RD
Blood Adv; 2019 Nov; 3(21):3360-3374. PubMed ID: 31698464
[TBL] [Abstract][Full Text] [Related]
45. Role of plasma cells in Waldenström macroglobulinaemia.
El-Ayoubi A; Wang JQ; Hein N; Talaulikar D
Pathology; 2017 Jun; 49(4):337-345. PubMed ID: 28483372
[TBL] [Abstract][Full Text] [Related]
46. Waldenström macroglobulinemia.
Treon SP; Hunter ZR; Castillo JJ; Merlini G
Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
[TBL] [Abstract][Full Text] [Related]
47. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK; Callander NS; Adekola K; Anderson LD; Baljevic M; Baz R; Campagnaro E; Castillo JJ; Costello C; D'Angelo C; Derman B; Devarakonda S; Elsedawy N; Garfall A; Godby K; Hillengass J; Holmberg L; Htut M; Huff CA; Hultcrantz M; Kang Y; Larson S; Lee H; Liedtke M; Martin T; Omel J; Robinson T; Rosenberg A; Sborov D; Schroeder MA; Sherbenou D; Suvannasankha A; Valent J; Varshavsky-Yanovsky AN; Snedeker J; Kumar R
J Natl Compr Canc Netw; 2024 Jan; 22(1D):e240001. PubMed ID: 38244272
[TBL] [Abstract][Full Text] [Related]
48. Kidney diseases associated with Waldenström macroglobulinemia.
Uppal NN; Monga D; Vernace MA; Mehtabdin K; Shah HH; Bijol V; Jhaveri KD
Nephrol Dial Transplant; 2019 Oct; 34(10):1644-1652. PubMed ID: 30380110
[TBL] [Abstract][Full Text] [Related]
49. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.
Muz B; de la Puente P; Azab F; Ghobrial IM; Azab AK
Mol Cancer Res; 2015 Feb; 13(2):263-72. PubMed ID: 25232031
[TBL] [Abstract][Full Text] [Related]
50. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Treon SP
Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
[TBL] [Abstract][Full Text] [Related]
51. [Waldenström macroglobulinemia: Japanese perception].
Sekiguchi N
Rinsho Ketsueki; 2019; 60(8):988-997. PubMed ID: 31484900
[TBL] [Abstract][Full Text] [Related]
52. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
Paulus A; Akhtar S; Caulfield TR; Samuel K; Yousaf H; Bashir Y; Paulus SM; Tran D; Hudec R; Cogen D; Jiang J; Edenfield B; Novak A; Ansell SM; Witzig T; Martin P; Coleman M; Roy V; Ailawadhi S; Chitta K; Linder S; Chanan-Khan A
Blood Cancer J; 2016 Nov; 6(11):e492. PubMed ID: 27813535
[TBL] [Abstract][Full Text] [Related]
53. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases.
Lin P; Mansoor A; Bueso-Ramos C; Hao S; Lai R; Medeiros LJ
Am J Clin Pathol; 2003 Aug; 120(2):246-53. PubMed ID: 12931555
[TBL] [Abstract][Full Text] [Related]
54. Current and Emerging Treatments for Waldenström Macroglobulinemia.
Grimont CN; Castillo Almeida NE; Gertz MA
Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
[TBL] [Abstract][Full Text] [Related]
55. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
56. Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with
Zhu J; Zhu X; Xie F; Ding Y; Lu H; Dong Y; Li P; Fu J; Liang A; Zeng Y; Xiu B
Pathol Oncol Res; 2023; 29():1611070. PubMed ID: 37151353
[No Abstract] [Full Text] [Related]
57. [Waldenström's macroglobulinemia].
Watanabe R
Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
[TBL] [Abstract][Full Text] [Related]
58. Reducing treatment toxicity in Waldenström macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Expert Opin Drug Saf; 2021 Jun; 20(6):669-676. PubMed ID: 33645373
[No Abstract] [Full Text] [Related]
59. Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells.
de Tute RM; Rawstron AC; Owen RG
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):211-3. PubMed ID: 23523273
[TBL] [Abstract][Full Text] [Related]
60. Waldenström macroglobulinemia and relationship to immune deficiency.
Levy A; Guidez S; Debiais C; Princet I; Bouyer S; Dindinaud E; Delwail V; Systchenko T; Moya N; Gruchet C; Sabirou F; Bobin A; Gardeney H; Nsiala L; Cailly L; Olivier G; Motard C; Fleck E; Corby A; Roul C; Denis G; Dieval C; Leleu X; Tomowiak C
Leuk Lymphoma; 2021 Nov; 62(11):2665-2670. PubMed ID: 34085595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]